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Abstract
Objective: The incidence of cranial radiotherapy (cRT)–induced central hypothyroidism 
(TSHD) in childhood brain tumor survivors (CBTS) is reported to be low. However, TSHD may 
be more frequent than currently suspected, as its diagnosis is challenging due to broad 
reference ranges for free thyroxine (FT4) concentrations. TSHD is more likely to be present 
when FT4 levels progressively decline over time. Therefore, we determined the incidence 
and latency time of TSHD and changes of FT4 levels over time in irradiated CBTS.
Design: Nationwide, 10-year retrospective study of irradiated CBTS.
Methods: TSHD was defined as ‘diagnosed’ when FT4 concentrations were below 
the reference range with low, normal or mildly elevated thyrotropin levels, and as 
‘presumed’ when FT4 declined ≥ 20% within the reference range. Longitudinal FT4 
concentrations over time were determined in growth hormone deficient (GHD) CBTS 
with and without diagnosed TSHD from cRT to last follow-up (paired t-test).
Results: Of 207 included CBTS, the 5-year cumulative incidence of diagnosed TSHD was 
20.3%, which occurred in 50% (25/50) of CBTS with GHD by 3.4 years (range, 0.9–9.7) 
after cRT. Presumed TSHD was present in 20 additional CBTS. The median FT4 decline 
in GH-deficient CBTS was 41.3% (P < 0.01) to diagnosis of TSHD and 12.4% (P = 0.02) in 
GH-deficient CBTS without diagnosed TSHD.
Conclusions: FT4 concentrations in CBTS significantly decline over time after cRT, also 
in those not diagnosed with TSHD, suggesting that TSHD occurs more frequently and 
earlier than currently reported. The clinical relevance of cRT-induced FT4 decline over 
time should be investigated in future studies.
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Childhood brain tumor survivors (CBTS) have an 
increased risk of developing central hypothyroidism due 
to damage of the hypothalamic–pituitary (HP) region, 
especially after exposure to cranial radiotherapy (cRT) 
(1, 2). The prevalence and latency times of cRT-induced 
HP dysfunction vary among patients, with growth 
hormone deficiency (GHD) usually occurring first and at 
a prevalence ranging from 29.0 to 39.1% (3). In contrast, 
central hypothyroidism primarily occurs after high-dose 
cRT, with a prevalence ranging between 2.6 and 14.9% (4).
Detection of central hypothyroidism may be 
challenging (5). Its diagnosis is generally based on plasma 
free thyroxine (FT4) concentrations below those of the 
reference range, in combination with low, normal or 
mildly elevated thyrotropin (TSH) levels. However, the 
use of population-based FT4 reference ranges as diagnostic 
criteria for central hypothyroidism is questionable because 
the variability of FT4 concentrations within individuals is 
small, in contrast with large interindividual differences (6, 
7). This suggests that an individual reduction in thyroid 
function within the reference range can be indicative of 
central hypothyroidism in CBTS who receive cRT. Previous 
studies have suggested that central hypothyroidism is 
underdiagnosed in patients with FT4 concentrations in 
the lower tertile of the reference range (8, 9).
Changes in FT4 concentration over time within one 
individual may be considered abnormal, even if they are 
maintained within the reference range (6). For this reason, 
adults with ≥ 20% reductions in FT4 concentrations 
may be presumed to have mild central hypothyroidism 
and may be replaced with levothyroxine therapy (LT4), 
although high-quality evidence supporting this is lacking 
(10). According to a recent guideline for surveillance of 
HP deficiencies (HPDs) in childhood cancer survivors, 
the diagnosis of central hypothyroidism is more likely 
when FT4 concentrations are progressively declining over 
time (4). A decline in FT4 concentrations, even those 
that remain within the lower tertile of the reference 
range, may thus be indicative of early damage to TSH-
secreting cells due to radiation exposure. However, this 
has not been systematically assessed, and the clinical 
consequences of declining FT4 concentrations in these 
patients remain unclear. To this end, we retrospectively 
analyzed the incidence and latency time of ‘diagnosed’ 
central hypothyroidism (i.e., FT4 concentrations below 
those of the reference range) and ‘presumed’ central 
hypothyroidism (i.e., decline in FT4 concentration ≥ 20% 
with levels in the lower tertile of the reference range 
during follow-up) in a nationwide cohort of longitudinally 
assessed CBTS who received cRT. Secondly, we assessed 
the clinical effects of central hypothyroidism on height 
and weight outcomes during follow-up.
Subjects and methods
Patients
All patients were younger than 18  years at the time 
of diagnosis of a primary brain tumor, excluding 
craniopharyngioma or a pituitary gland tumor, between 
January 2002 and December 2012 (n = 258). The patients 
received cranial or craniospinal irradiation and had 
survived ≥ 2  years after diagnosis with either stable 
residual disease or no evidence of disease after completion 
of therapy at the time of follow-up. The methodology 
we used for patient selection has been described in detail 
(11). Because both the pituitary and thyroid gland were 
exposed to radiotherapy during craniospinal irradiation, 
we limited the interference of thyroidal dysfunction on 
thyroid function parameters by excluding all patients with 
overt primary or subclinical (primary) hypothyroidism, as 
defined below (n = 39). In addition, patients with HPDs 
before receiving cRT were excluded (n = 12). Because the 
data were collected retrospectively, our institutional 
review board determined that the Act on Medical Research 
Involving Human Subjects did not apply to our study and 
provided a waiver for informed consent.
Definitions used for endocrine deficiencies
Central hypothyroidism
Diagnosed central hypothyroidism was defined as FT4 
concentrations below those of each institutional age-
specific reference range, in combination with low, normal 
or mildly elevated TSH concentrations (i.e. <7 mIU/L) or 
by the use of LT4 for documented diagnoses of central 
hypothyroidism. Presumed central hypothyroidism was 
defined as ≥ 20% decline in individual FT4 concentration 
that remained within the lower tertile of the age-specific 
reference intervals from the time of cRT to last follow-up, 
in combination with normal TSH concentrations.
Primary hypothyroidism
Overt primary hypothyroidism was defined as elevated 
plasma TSH concentrations (i.e. ≥7 mIU/L) in combination 
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with low FT4 concentrations, according to those of 
each institutional age-specific reference range or by LT4 
administration for documented diagnoses of primary 
hypothyroidism. Subclinical primary hypothyroidism 
was defined as FT4 concentrations within those of each 
institutional age-specific reference range in combination 
with raised TSH levels at last follow-up.
Growth hormone deficiency
GHD was defined as insufficient peak responses after one 
or more GH stimulation tests (< 20 mU/L) or a peak GH 
<30 mU/L in combination with an insulin-like growth 
factor-1 (IGF1) concentration <−2 standard deviation 
score (SDS). The date of GHD diagnosis was recorded as 
the date that the last GH stimulation test was performed 
to establish GHD diagnosis.
Adrenocorticotropic hormone deficiency
Adrenocorticotropic hormone deficiency (ACTHD) was 
defined by the use of hydrocortisone maintenance or 
substitution for suspected hypocortisolism, as documented 
by the treating endocrinologist at the last follow-up.
Luteinizing hormone and follicle-stimulating 
hormone deficiency
Luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) deficiency (LH/FSHD) was defined by 
repeatedly low LH and/or FSH concentrations in the absence 
of pubertal development (girls aged >12  years, puberty 
stage B1; boys aged >13 years, testes volumes < 4 mL) or by 
use of estrogens or testosterone treatment for documented 
LH/FSHD cases at last follow-up.
Data collection
Data were retrospectively collected from patient medical 
records, which included demographic and tumor-related 
characteristics, treatment modalities, anthropometrics 
(i.e., height and weight) and use of antiepileptic drugs 
until the last follow-up for each patient. The cRT dose 
comprised the total cRT doses prescribed for tumor 
treatment. All endocrine laboratory measurements, 
including basal measurements of IGF1, FT4 and TSH, as 
well as dynamic testing results for GHD, were collected 
together with the age-specific reference ranges for FT4 
and TSH concentrations of each institution. The lower 
limits of the FT4 reference ranges varied between 8 
and 12.5 pmol/L, and the upper limits ranged from 18 
to 26 pmol/L. The lower tertiles of each institutional-
specific reference ranges were defined by dividing the 
difference between the upper and lower limits by three. 
The lower limits of the TSH assays were between 0.3 
and 0.5 mIU/L, whereas the highest reported upper limit 
was 5.0 mIU/L
Statistical analyses
Descriptive analyses were performed for the prevalence 
and cumulative incidence of HPDs in all CBTS who 
received cRT. For diagnosed central hypothyroidism, 
presumed central hypothyroidism, and GHD, the latency 
time was also examined. Because we assumed that GHD 
has the shortest latency time after cRT treatment, the 
presence or absence of GHD during follow-up was 
used to categorize the cohort into distinct subgroups. 
The first subgroup consisted of CBTS who experienced 
GHD during follow-up. Changes in FT4 concentration 
(absolute and percent changes in FT4 (∆FT4)) were 
compared at the following time points with paired 
analyses: (1) at the time of cRT start, (2) at diagnosis of 
GHD, (3) after starting GH treatment and (4) at diagnosis 
of central hypothyroidism or at the last follow-up if 
central hypothyroidism was not diagnosed. A second 
subgroup consisted of all CBTS who received cRT but 
did not receive diagnoses of GHD or other HPDs at 
follow-up. Changes in FT4 concentration (absolute and 
∆FT4) were compared at the time of cRT start and at the 
last follow-up. Missing values are indicated in the figures 
and explained in the legends.
Between-group differences were examined by Student 
t-tests for continuous data with normal distributions 
and χ2 or Fisher exact tests for categorical data. Non-
normally distributed data were analyzed by Mann–
Whitney U tests. Cumulative incidence was calculated 
by using the Kaplan–Meier survival method (1 minus 
Kaplan–Meier probability). Paired t-tests were used to 
evaluate differences in ∆FT4 concentrations within 
groups, and Wilcoxon signed-rank tests were used for 
TSH concentrations. Serial FT4 and TSH measurements 
for each individual were obtained from the same clinical 
laboratories to allow proper paired analyses. A P value less 
than 0.05 was considered statistically significant. Analyses 
were performed with SPSS 21.0 for Windows (IBM SPSS 
System Inc). GraphPad Prism 7.02 was used to generate 
figures for longitudinal data.
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We included a total of 207 CBTS who received cRT in our 
study (Fig.  1 and Table  1). The median follow-up time 
after brain tumor diagnosis was 6.9 years (range, 2.0–13.3) 
and 6.1 years (range, 0.2–12.7) after cRT start. The median 
cRT dose was 54 Gy (range, 12.5–72.0).
Incidence of anterior pituitary deficiencies
Sixty-eight of 207 (32.9%) CBTS experienced one or more 
HPDs after exposure to cRT. Thirty-three of these (48.5%) 
experienced one HPD, and 35 (51.5%) experienced multiple 
HPDs at last follow-up. The 5-year cumulative incidence was 
31.4% (95% confidence interval (CI) 21.8–41.4) for GHD, 
20.3% (95% CI 10.7–32.1) for central hypothyroidism, 
6.6% (95% CI 0.7–22.6) for ACTHD, and 3.1% (95% CI 
0.02–23.9) for LH/FSHD. The latency time of GHD and 
central hypothyroidism after cRT start was 2.5 years (range, 
0.6–7.4) and 2.7  years (range, 0.3–9.7), respectively. The 
prevalence of HPDs at last-follow-up was 28.5% (59/207) 
for GHD, 20.3% (42/207) for central hypothyroidism, 
6.3% (13/207) for ACTHD and 4.3% (9/207) for LH/FSHD. 
Figure 2 summarizes the prevalence and overlap of all HPDs. 
The prevalence of antiepileptic drug use was similar among 
CBTS with and without diagnosed central hypothyroidism 
(17.6 vs 11.5%, P = 0.55).
Nine of the 68 CBTS (13.2%) experienced an HPD 
other than GHD (i.e., central hypothyroidism, ACTHD, 
LH/FSHD, or a combination of these). In two of these 
nine CBTS, GH stimulation tests were performed, ruling 
out GHD. In two other CBTS, low IGF1 concentrations 
were found, suggestive of GHD. In the 59 CBTS with 
GHD, nine (15.3%) had central hypothyroidism before 
GHD diagnosis. In these CBTS, IGF1 concentrations at 
diagnosis of central hypothyroidism were low (median 
IGF1 SDS, −2.57; range, −5.11 to −1.79).
Longitudinal effect of cranial radiotherapy on free 
thyroxine concentrations
CBTS with GHD
We performed paired analyses of the longitudinal FT4 
concentrations in 50 CBTS who did not have central 
hypothyroidism before GHD. Their median FT4 
concentrations declined by 9.0% (−1.4 pmol/L) from cRT 
start to GHD diagnosis (P < 0.01) after a median follow-up 
period of 1.7 years (Fig. 3). In the 45 CBTS who subsequently 
received GH treatment, a 14.9% (−2.0 pmol/L) decline in 
FT4 occurred after a median period of 0.6 years (P < 0.01). 
The total median decline of FT4 was 26.1% (−3.5 pmol/L) 
between start cRT and after GH treatment (P < 0.01). TSH 
concentrations did not significantly change over time 
(median TSH at GHD diagnosis, 2.7 mIU/L vs median TSH 
at GH treatment start, 2.8 mIU/L; P = 0.44).
Figure 1
Flow chart of retrospective study cohort. ACTHD, 
adrenocorticotropic hormone deficiency; CBTS, 
childhood brain tumor survivors; cRT, cranial 
radiotherapy; FT4, free thyroxine; FU, follow-up 
time after diagnosis; GHD, growth hormone 
deficiency; HPD, hypothalamic–pituitary 
deficiency; LH/FSHD, luteinizing hormone–follicle-
stimulating hormone deficiency. aFT4 
concentrations were longitudinally analyzed in 
this cohort at cRT start, at GHD diagnosis, after 
GH treatment, at central hypothyroidism 
diagnosis, or at last follow-up without central 
hypothyroidism diagnosis. bFT4 concentrations 
were longitudinally analyzed at cRT start and at 
last-follow-up in this cohort.
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In 25 of the 50 CBTS with GHD, central hypothyroidism 
was diagnosed 3.4 years (range, 0.9–9.7) after cRT start and 
0.7 years (range, 0.1–5.9) after GHD diagnosis. The median 
FT4 decline in these CBTS was 41.3% (−6.1 pmol/L) from 
cRT start to central hypothyroidism diagnosis (Fig.  4A) 
(P < 0.01). In these CBTS, central hypothyroidism may 
have been already presumed 2.4  years after cRT start. 
In the 25 CBTS with GHD who did not have diagnosed 
central hypothyroidism, the median decline in FT4 
concentration was 12.4% (−2.1 pmol/L) from cRT start 
to last follow-up (P = 0.02). In five of these 25 CBTS, 
presumed central hypothyroidism was present. CBTS 
with diagnosed central hypothyroidism were most often 
medulloblastoma survivors and were older at diagnosis, 
Table 1 Demographic and treatment characteristics of the study cohort (n = 207).
Characteristic No. %
Sex
 Male 125 60.4
 Female 82 39.6
Age at diagnosis brain tumor (years)
 Median (range) 8.9 (0.1–17.7)
Age at follow-up (years)
 Median (range) 16.2 (4.7–27.4)
Follow-up time after brain tumor diagnosis (years)
 Median (range) 6.9 (2.0–13.3)
Follow-up time after cRT (years)
 Median (range) 6.1 (0.2–12.7)
Histology
 Medulloblastoma 63 30.4
 Low-grade glioma 45 21.7
 High-grade glioma 13 6.3
 sPNET 7 3.4
 Ependymoma 43 20.8
 Choroid plexus tumor 1 0.5
 Germ-cell tumor 15 7.2
 ATRT 5 2.4
 Othera 8 3.9
 Without histology 7 3.4
Location of primary tumor
 Infratentorial region 107 51.7
 Supratentorial region 80 38.6
 Suprasellar region 20 9.7
Hydrocephalus at diagnosisb
 Yes 142 68.6
 No 65 31.4
Single and combined treatment modalities applied at any time
 cRT only 5 2.4
 Neurosurgery + cRT 84 40.6
 cRT + CT 2 1.0
 Neurosurgery + cRT + CT 116 56.0
cRT localization
 Cranial 132 63.8
 Craniospinal 75 36.2
Age at primary cRT (years)
 Median (range) 9.7 (1.5–22.9)
 <5 41 19.8
 5–10 67 32.4
 >10 99 47.8
Total cRT dose (Gy)
 Median (range) 54.0 (12.5–72.0)
Recurrence/progression requiring treatment
 Yes 63 30.4
 No 144 69.6
aIncludes meningioma (n = 4), schwannoma (n = 3), and desmoplastic small-round-cell tumor (n = 1). bHydrocephalus was defined as the presence of 
increased ventricle width during magnetic resonance imaging.
ATRT, atypical teratoid rhabdoid tumor; CT, chemotherapy; cRT, cranial radiotherapy; sPNET, supratentorial primitive neuro-ectodermal tumor.
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cRT start and follow-up than were CBTS without 
central hypothyroidism. The characteristics of the 50 
CBTS with GHD and with or without diagnosed central 
hypothyroidism are listed in Table 2.
CBTS without growth hormone or other 
hypothalamic–pituitary deficiencies
Of the CBTS who received cRT but did not have HPDs 
during follow-up (n = 139), the median ΔFT4 was −4.4% 
(−0.7 pmol/L) from cRT start to last follow-up (P = 0.02) 
after a median time of 4.2  years (range, 0.2–11.3). 
Presumed central hypothyroidism was present in 15 of 
these CBTS (Fig. 4B).
Clinical effects on height and weight
All CBTS who received cRT but did not have GHD were 
included for analysis of height and weight (n = 148). 
Neither height or BMI SDSs of patients with presumed 
and diagnosed central hypothyroidism were significantly 
different from those of patients without central 
hypothyroidism.
Discussion
We performed a large-cohort study of CBTS who received 
cRT and found a high incidence of diagnosed central 
hypothyroidism. More importantly, our longitudinal 
analyses revealed marked declines in FT4 concentrations 
over time, with a decline of even >40% from initial FT4 
values before the diagnosis of central hypothyroidism was 
made. In addition, a decline in FT4 concentration ≥20% 
(i.e. presumed central hypothyroidism) was present in 20 
additional CBTS.
Central hypothyroidism in CBTS has been reported 
to be infrequent or absent after low-dose cRT (12, 13, 14, 
15, 16, 17). The relatively high (20.3%) 5-year cumulative 
Figure 2
Prevalence and overlap of hypothalamic-pituitary deficiencies in 
childhood brain tumor survivors who received cranial irradiation.
Figure 3
Scatter dot plot (median with interquartile range) of absolute FT4 
concentrations at cRT start, before GHD diagnosis, and after GH treatment 
start. Available FT4 concentrations for 50 CBTS with GHD were compared. 
FT4 concentrations before cRT start could be retrieved for 24 CBTS. In the 
remaining 26 CBTS, the first measured FT4 concentration after cRT start 
was deemed the baseline value for cRT start. FT4 concentrations could be 
compared at cRT start and at GHD diagnosis for 46 CBTS. FT4 
concentrations could be compared at GHD diagnosis and after GH 
treatment for 38 CBTS. Median FT4 concentrations declined from cRT start 
to GHD diagnosis (P < 0.01; 95% CI 0.82–2.14; paired t-test, n = 46) and 
after GH treatment (P < 0.01; 95% CI 1.06–3.33; paired t-test, n = 38). CBTS, 
childhood brain tumor survivors; cRT, cranial radiotherapy; FT4, free 
thyroxine; GH, growth hormone; GHD, growth hormone deficiency.
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incidence of central hypothyroidism in our cohort may 
be due to the high-dose cRT that these patients received, 
as the vulnerability of the HP–thyroid axis is highly dose 
dependent (18, 19). Our observations are concordant 
with the 4-year cumulative incidence (23%) reported in 
a large cohort study including CBTS who received cRT 
doses ≥ 40 Gy (20).
We demonstrated a clear decline in FT4 concentrations 
over time that occurred simultaneously with or preceded 
GHD diagnosis. In previous studies, a decline in total 
T4 concentrations after cRT by 1.5% per year has been 
reported (13). However, in one study, only children who 
received low-dose cRT were included (15–24 Gy), and 
only single FT4 concentrations from different CBTS were 
correlated with follow-up time. In another study, the 
same cross-sectional analysis was applied to a cohort of 
CBTS receiving high-dose cRT (53.6 Gy), and an inverse 
association between serum FT4 concentrations and 
follow-up times was reported (21).
The usefulness of the population-based FT4 reference 
ranges used to establish central hypothyroidism 
diagnoses is debatable (22). Diagnostic tests, such as 
dynamic TRH testing or the use of the nocturnal TSH 
rise have been suggested as alternative markers of central 
hypothyroidism (8). However, dynamic testing of the HP–
thyroid axis requires hospital admission, limiting its use 
as a screening tool. In addition, possible abnormalities 
of TSH dynamics upon dynamic testing may represent 
subtle variations and may not be indicative for central 
hypothyroidism (23). Because intraindividual differences 
in FT4 concentrations in healthy subjects are small 
(24), some guidelines recommend treatment with LT4 
when ≥ 20% declines in FT4 concentrations are observed 
(10). Following these guidelines, our findings suggest that 
treatment could have been provided 1 year earlier in CBTS 
with diagnosed central hypothyroidism and might have 
been started in an additional 20 CBTS with presumed 
central hypothyroidism.
Several factors may affect FT4 concentrations. In 
general, FT4 concentrations decrease with age, especially 
when entering puberty (25). This may partially explain 
why the CBTS in our study with diagnosed central 
hypothyroidism were older than those without diagnosed 
central hypothyroidism. However, the follow-up time of 
our cohort (6.9  years) was too short to support a large 
interference of age with the observed declining FT4 
concentrations. Moreover, the follow-up times of CBTS 
with GHD and with and without diagnosed central 
hypothyroidism were similar, suggesting that age and 
not follow-up time unmasked the presence of central 
Figure 4
Scatter dot plot of the percent change in FT4 concentration (∆FT4), in 
relation to absolute FT4 concentrations of all CBTS with GHD and without 
GHD or other HPDs who received cRT. (A) CBTS with GHD (n = 50); ∆FT4 
was calculated by comparing FT4 concentrations at cRT start to central 
hypothyroidism diagnosis or to last follow-up if central hypothyroidism 
was not diagnosed. Central hypothyroidism was presumed when FT4 
levels declined ≥20% and were in the lower tertile of the reference range 
(n = 5). (B) CBTS without GHD or other HPDs (n = 139); ∆FT4 was calculated 
by comparing FT4 concentrations at cRT start to last follow-up. FT4 
concentrations before cRT start could be retrieved for 64 CBTS. The first 
measured FT4 concentration after the cRT start was deemed the baseline 
FT4 value at cRT start for the remaining 75 CBTS. FT4 concentrations 
could be compared between baseline and last follow-up for 98 CBTS. 
Central hypothyroidism was presumed when FT4 declined ≥20% and was 
in the lower tertile of the reference range (n = 15). Dashed lines indicate 
∆FT4 of −20%. CBTS, childhood brain tumor survivors; cRT, cranial 
radiotherapy; FT4, free thyroxine; GHD, growth hormone deficiency; HPD, 
hypothalamic–pituitary deficiency.
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hypothyroidism in our cohort. Nutritional status, BMI and 
antiepileptic drug use are also factors that may affect thyroid 
function parameters. In our cohort, we did not observe 
significant changes in BMI over time and the prevalence 
of antiepileptic drug use was similar among CBTS with 
and without diagnosed central hypothyroidism. However, 
start and stop dates of antiepileptic drug use had not been 
retrieved from medical charts. In addition, information 
regarding other drugs that potentially influenced thyroid 
function parameters was not collected. This limits our 
ability to draw strong conclusions about potential 
interference of (antiepileptic) drug use and thyroid 
function parameters. Finally, initiation of GH treatment 
may induce changes in FT4 and TSH concentrations, 
possibly by increased T4 to T3 conversion and inhibition 
of TSH secretion (26). Although these changes are often 
Table 2 Demographic and treatment characteristics of growth hormone deficient CBTS, with and without subsequent central 
hypothyroidism.
Characteristic
No diagnosed central 
hypothyroidism after  
GHD (n = 25)
Diagnosed central 
hypothyroidism after  
GHD (n = 25)
PNo. % No. %
Sex 0.76
 Male 17/25 68.0 18/25 72.0
 Female 8/25 32.0 7/25 28.0
Age at diagnosis brain tumor (years) <0.01b
 Median (range) 4.4 (0.6–12.3) 9.3 (2.4–13.1)
Age at follow-up (years) <0.01b
 Median (range) 12.6 (5.1–23.1) 16.9 (9.8–25.0)
Follow-up time after brain tumor diagnosis (years) 0.19
 Median (range) 8.2 (2.5–13.3) 8.9 (3.3–12.4)
Histology <0.01b
 Medulloblastoma 15/25 60.0 20/25 80.0
 Low-grade glioma 1/25 4.0 5/25 20.0
 sPNET 1/25 4.0 – –
 Ependymoma 5/25 20.0 – –
 ATRT 1/25 4.0 – –
 Meningioma 1/25 4.0 – –
 Without histology 1/25 4.0 – –
Location of primary tumor 1.00
 Infratentorial region 21/25 84.0 21/25 84.0
 Supratentorial region 1/25 4.0 – –
 Suprasellar region 3/25 12.0 4/25 16.0
Hydrocephalus at diagnosisa 0.51
 Yes 20/25 80.0 18/25 72.0
 No 5/25 20.0 7/25 28.0
Single and combined treatment modalities applied at any time 0.67
 Neurosurgery + cRT 3/25 12.0 2/25 8.0
 cRT + CT 1/25 4.0 – –
 Neurosurgery + cRT + CT 21/25 84.0 23/25 92.0
cRT localization 0.05
 Cranial 9/25 36.0 3/25 12.0
 Craniospinal 16/25 64.0 22/25 88.0
Age at primary cRT (years) <0.01b
 Median (range) 5.1 (1.8–12.4) 9.9 (3.0–15.6)
 <5 11/25 44.0 2/25 8.0
 5–10 9/25 36.0 11/25 44.0
 >10 5/25 20.0 12/25 48.0
Total cRT dose (Gy) 0.72
 Median (range) 54.0 (15.0–68.0) 54.0 (45.0–72.0)
Recurrence/progression requiring treatment 0.33
 Yes 8/25 32.0 5/25 20.0
 No 17/25 68.0 20/25 80.0
aHydrocephalus was defined as the presence of increased ventricle width during magnetic resonance imaging. bSignificant P values.
ATRT, atypical teratoid rhabdoid tumor; CT, chemotherapy; CBTS, childhood brain tumor survivors; cRT, cranial radiotherapy; sPNET, supratentorial 
primitive neuro-ectodermal tumor.
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transient in non-GH-deficient individuals, in patients 
with organic GH deficiency or multiple pituitary hormone 
deficiencies, alterations in thyroid function parameters 
seem more pronounced and result in the unmasking of 
central hypothyroidism (27).
The clinical significance of mild (i.e., presumed) 
central hypothyroidism is an issue of debate. Growth 
acceleration in children who receive GH therapy occurs 
only after LT4 treatment in cases of concomitant central 
hypothyroidism (28). Another study reported that reduced 
patient heights were found at start of GH treatment in 
children with multiple pituitary hormone deficiencies, 
as compared to the heights of children with true isolated 
GHD (29). These findings suggest that when unrecognized 
central hypothyroidism is present in children with GHD, 
it may have already affected linear growth. We did not 
find any adverse effects on height or BMI from declining 
FT4 concentrations in our cohort. However, these clinical 
parameters were not systematically assessed, and a large 
proportion of CBTS had not yet reached adult height. 
Therefore, definite conclusions regarding the clinical 
consequences of declining FT4 concentrations cannot be 
drawn and should be assessed in future studies.
Patients who experience central hypothyroidism after 
GH therapy start have a lower quality of life than do patients 
who remain euthyroid. This difference in quality of life is 
reversible, as it was shown to resolve after LT4 treatment in 
adults with hypothyroidism (9). Central hypothyroidism 
may decrease left ventricular ejection fraction  in patients 
with pituitary disease, even when FT4 concentrations 
remain within the lower range of the reference interval (30). 
CBTS may have an altered metabolic state, increasing their 
risk for dyslipidemia and heart disease because of previous 
exposures to chemotherapy (e.g., alkylating agents), 
impaired neurologic function, reduced physical activity, 
and comorbid endocrine deficiencies. Suboptimal thyroid 
hormone concentrations may further negatively influence 
the metabolic state. These arguments may be used to advocate 
timely and adequate supplementation of LT4 in CBTS with 
a history of cRT aiming to restore FT4 concentrations to 
the highest third of the reference range to encourage linear 
growth potential and improve quality of life, metabolic state 
and cardiac health. The potential benefits of treatment, 
however, should be considered in the context of the 
possible negative aspects of overdiagnosis, overtreatment, 
daily medication administration and frequent blood tests. 
Prospective studies with systematic screening for central 
hypothyroidism are required to define the exact prevalence, 
most optimal diagnostic criteria, and subsequent clinical 
relevance of mild central hypothyroidism in CBTS.
The comprehensive nature and the intraindividual 
analyses of FT4 concentrations over time exemplify the 
strengths of our study. In addition, we evaluated thyroid 
function parameters only after completion of therapy, 
excluding FT4 declines from nonthyroidal illnesses or the 
effects of supportive care drugs such as dexamethasone 
on thyroid function determinants (31). Nevertheless, 
the retrospective design, lack of screening guidelines 
for HPDs in CBTS, and nonsystematic reporting of HP–
thyroid function parameters, resulting in missing values 
for a proportion of CBTS, are limitations of our study. In 
addition, the lack of systematic and repetitive screening 
may have underestimated the true prevalence of HPDs 
in our cohort, given the time dependent character of 
cRT-induced HPDs. Especially the occurrence of ACTHD 
might have been under-represented in our cohort, as 
dynamic testing was only performed in a minority of all 
CBTS. Moreover, we defined baseline FT4 concentrations 
for individual CBTS as FT4 concentrations at cRT start. 
However, this may underestimate actual FT4 baseline 
concentrations, as illnesses before cRT were not considered. 
This may account for our observation of increased FT4 
concentrations during follow-ups in a substantial number 
of CBTS. However, this also suggests that the actual FT4 
declines in CBTS with presumed central hypothyroidism 
may have been even larger. A possible coexistence of 
thyroid-initiated hypothyroidism (leading to combined 
or mixed hypothyroidism) after craniospinal radiotherapy 
should be considered because both the HP and thyroid 
glands are included in the radiation field. We were not able 
to ascertain detailed cRT dose information for the pituitary 
or thyroid gland. Therefore, no conclusion can be drawn 
upon the risk for central hypothyroidism in relation to 
radiation dose. Also, the HP region of the GH-deficient 
and nonGH-deficient groups may have been exposed to 
different cRT doses, which may have biased the comparison 
results between both groups. In addition, other tumor 
and treatment characteristics, such as tumor involvement 
in the HP region, should be considered as cause for the 
occurrence of central hypothyroidism at follow-up. 
Secondly, in patients exposed to craniospinal irradiation, 
it can be difficult to make a clear distinction between 
primary and central hypothyroidism, and combined 
forms of hypothyroidism may be present. Declines in FT4 
concentration may have been exacerbated by radiation 
damage to the thyroid gland. For this reason we have used 
stringent diagnostic criteria for central hypothyroidism, In 
addition, the large proportion of CBTS with known GHD 
included in our analysis suggests that these patients may 
have already experienced cRT-induced HP damage.
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In conclusion, FT4 concentrations of irradiated CBTS 
significantly decline over time, suggesting that high-dose 
cRT causes more frequent and earlier damage to TSH- 
or T4-secreting cells than is currently reported. Future 
prospective studies are required to confirm our findings and 
the clinical relevance of cRT-induced FT4 decline in CBTS.
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